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ABSTRACT 
Context Organ failure is a major determinant of mortality in patients with acute pancreatitis. These patients usually require 
admission to high dependency or intensive care units and consume considerable health care resources. Given a low incidence 
rate of organ failure and a lack of large non-interventional studies in the field of acute pancreatitis, the characteristics of 
organ failure that influence outcomes of patients with acute pancreatitis remain largely unknown. Therefore, the Pancreatitis 
Across Nations Clinical Research and Education Alliance (PANCREA) aims to conduct a meta-analysis of individual patient 
data from prospective non-interventional studies to determine the influence of timing, duration, sequence, and combination 
of different organ failures on mortality in patients with acute pancreatitis. Methods Pancreatologists currently active with 
acute pancreatitis clinical research will be invited to contribute. To be eligible for inclusion patients will have to meet the 
criteria of acute pancreatitis, develop at least one organ failure during the first week of hospitalization, and not be enrolled 
into an intervention study. Raw data will then be collated and checked. Individual patient data analysis based on a logistic 
regression model with adjustment for confounding variables will be done. For all analyses, corresponding 95% confidence 
intervals and P values will be reported. Conclusion This collaborative individual patient data meta-analysis will answer 
important clinical questions regarding patients with acute pancreatitis that develop organ failure. Information derived from 
this study will be used to optimize routine clinical management and improve care strategies. It can also help validate 
outcome definitions, allow comparability of results and form a more accurate basis for patient allocation in further clinical 
studies. 
 
INTRODUCTION 
Organ failure is a major determinant of mortality [1, 
2, 3, 4, 5] in patients with acute pancreatitis and this 
has been highlighted in the new international 
multidisciplinary classification of acute pancreatitis 
severity as the “systemic” determinant [1, 2]. 
Patients who develop organ failure usually require 
admission to high dependency unit or intensive care 
unit (ICU). These patients are among the most 
resource demanding in health care systems [6, 7]. 
ICUs currently represent the largest clinical cost 
department in hospitals, with expenses estimated to 
be up to 20% of a hospital’s budget [8, 9], and costs 
per day is three to five-fold greater than in general 
wards [10, 11, 12]. 
Several aspects of organ failure have been studied, 
although many questions remain. 
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1) Dynamics of Organ Failure 
It is widely accepted that local pancreatic 
inflammation is the initiating stimulus for a 
systemic inflammatory response. This, in turn, may 
result in the development of organ failure and 
contribute to death in patients with acute 
pancreatitis. The importance of the duration and 
reversibility of organ failure has been well 
recognized in the last decade. It has been shown 
that patients with worsening organ failure as well 
as those with persistent organ failure have a 
significantly higher mortality rate [13, 14, 15, 16, 
17]. A study from the United Kingdom [14] enrolled 
290 patients across 18 centers and found that 
resolution of organ failure within 48 hours was 
associated with a better prognosis compared to 
patients with organ failure for more than 48 hours. 
This was irrespective of whether the organ failure 
was present on admission or developed later. 
Another study conducted in Scotland [13] on 121 
patients found that patients with worsening organ 
failure and poor response to treatment have a 
higher mortality rate. A study from New Zealand 
also demonstrated that the initial physiological 
response to intensive care treatment was a better 
predictor of outcome and mortality in patients with 
acute pancreatitis [17]. These studies underscore 
the dynamic nature of organ failure and the 
importance of monitoring the response to 
treatment. 
2) Number of Failed Organs 
The concept of multiple organ failure was first 
described in the 1970s [18], since then, a large 
number of definitions and acronyms have been 
proposed [19]. A modern definition for multiple 
organ failure in patients with acute pancreatitis 
refers to the failure of two or more organ systems 
[20]. Multiple organ failure has been shown to be 
the leading cause of death in a variety of clinical 
settings [21, 22]. Mortality rate in acute pancreatitis 
patients with multiple organ failure has been 
reported to be up to 100% [20, 23, 24, 25, 26] and 
there is a significant correlation between the 
number of organ failures and mortality [27]. A large 
population based retrospective cohort study on all 
deaths due to acute pancreatitis in Scotland 
included data from 1,024 patients and found that 
63% of fatalities had failure of at least two organ 
systems [28]. 
3) Which Organs Fail 
The Atlanta classification for severity of acute 
pancreatitis advocated four organ systems 
(cardiovascular, pulmonary, renal and gastro-
intestinal bleeding) to classify the severity of acute 
pancreatitis [22]. The European Society of Intensive 
Care Medicine since advocated a scoring system 
that includes six major organ systems to describe as 
quantitatively and objectively as possible the degree 
of organ dysfunction over time in critically ill 
patients [29]. This scoring system, termed the 
Sepsis-related Organ Failure Assessment (SOFA) 
score, has been widely used in a variety of disease 
settings [30, 31, 32]. The organ systems used in the 
SOFA score are respiratory, cardiovascular, 
coagulation, hepatic, renal and central nervous 
systems. The number of organ systems that have 
been included in studies have varied from three [4], 
four [27, 33], six [34, 35] to eight [27]. Based on the 
2011 global survey of pancreatologists [36], the 
consensus is that three organ systems (respiratory, 
cardiovascular and renal) fail most frequently in 
patients with acute pancreatitis and is of much 
more prognostic importance than failure of other 
systems [4, 35, 37, 38]. Presence/absence of organ 
failure in each of these three systems is used in the 
new international multidisciplinary classification of 
acute pancreatitis severity [1]. 
4) Combination and Sequence of Organ Failures 
A prospective multicenter inception cohort analysis 
[39] of 17,440 ICU admissions (all cases and not 
confined to patients with acute pancreatitis) treated 
from 1988 to 1990 and 5,677 ICU admissions 
treated from 1979 to 1982 found that combinations 
of organ systems and the organ system that failed 
had an impact on outcome. They found that the 
profile of physiologic abnormalities substantially 
influences mortality. For example, mortality rate for 
patients with two organ system failures varied from 
20% (combination of hematologic and 
cardiovascular failure) to 76% (combination of 
cardiovascular and neurologic failures). 
In patients with acute pancreatitis, a retrospective 
study by Halonen et al. [35] demonstrated that 
different combinations of two organ system failures 
have different mortality rates with the highest 
mortality rate (91%) associated with the 
combination of hepatic and renal failures. They also 
showed that hepatic failure, renal failure, previous 
cardiovascular medication and cardiovascular 
failure were independent factors that are associated 
with hospital mortality. Some limitations of this 
study include the retrospective design, the 
relatively small cohort of patients (n=113) and a 
selection bias because not all patients with organ 
failure were included. 
Another study looked at sequential system failure in 
patients with acute renal failure after rupture of 
abdominal aortic aneurysms [40]. The authors 
showed that there was a similar progression of 
organ system failures in all patients. This sequence 
unfolded more slowly in patients that survived 
longer and developed more quickly in those 
surviving for shorter periods. This “predictability” 
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of sequence failure in organ failure, if confirmed, 
may have important implications in the allocation of 
resource and targeted treatments directed towards 
slowing disease progression and reducing mortality. 
Limitations of Current Knowledge About Organ 
Failure 
First, most studies have been single center cohort 
studies [15, 16, 41, 42, 43, 44] without sufficient 
statistical power to investigate all aspects of organ 
failure and their effect on mortality. This is likely 
because of relatively low incidence of acute 
pancreatitis patients with organ failure. The annual 
incidence rate in the United States is 2-4 cases of 
complicated acute pancreatitis per year per 100,000 
adults, and only a fraction of them develop organ 
failure [45]. 
Second, there are some studies in which the cohorts 
from larger multi-center studies are part of 
interventional studies [14, 46] which makes any 
inference about disease course and outcomes in 
general, and organ failure in particular, inherently 
biased. This is because any studied intervention is 
designed to alter the natural course of the disease. 
Other larger studies are limited by selection bias, 
such as using preselected cohorts of patients with 
other determinants of outcome (e.g., pancreatic 
necrosis) or only selected patients who had a 
contrast enhanced CT scan [33, 47, 48, 49]. This 
selection bias does not allow a valid inference about 
the course and outcomes of organ failure. 
Third, there is a relatively limited body of evidence 
in the literature about the relative importance of 
different characteristics of organ failure such as 
number, timing, duration, sequence, and 
combination [1]. Moreover, there is limited 
evidence to validate the definitions of these 
characteristics. Valid outcome definitions are 
essential for quality research, allowing 
comparability of results among centers and the 
ability to monitor changes in between different 
centers over time [50]. 
Unanswered Questions About Organ Failure 
Limitations and bias in the existing literature 
highlights the need for purportedly designed non-
interventional studies to answer a number of key 
questions relating to the characteristics of organ 
failure in acute pancreatitis [51] and how they are 
linked to mortality (Figure 1). These include, but are 
not limited to the following questions: 
1) What is the relative incidence of each organ 
failure? 
2) What is the relationship between number of 
organ failures and mortality? 
3) What is the most common sequence in failing 
systems? 
4) What is the timing of onset for each organ failure 
and its effect on mortality? 
5) How is mortality affected by the duration of each 
system failure? 
6) What is the relative incidence of the specific 
sequences of organ failure and its effect on 
mortality? 
7) What is the relative incidence of each 
combination of two system failures and its effect on 
mortality? 
Answering the Questions by Conducting an 
Individual Patient Data Meta-Analysis 
Pooled analysis of prospective data from individual 
patients in all the available studies has been 
regarded as the gold standard in evidence synthesis 
generation [52, 53] and has provided the best 
approach to answer questions pertinent to the 
natural course of disease [54]. The methods and 
advantages of individual patient data (IPD) meta-
analysis have been well described [55, 56]. IPD 
meta-analysis provides the least biased and most 
reliable means of addressing questions not 
satisfactorily answered by individual clinical studies 
[57]. This is because it does not rely on published 
information alone and includes all available study 
data, thus allowing for detailed checks of the 
integrity and completeness of data and also 
reducing selection and publication bias. By 
including data from multiple centers, it provides a 
stronger endorsement of results, better clarification 
and provision of updated follow up information, as 
well as a collaboration for further research [58]. In 
Figure 1. Current knowledge and unanswered questions 
regarding patients with acute pancreatitis that develop organ 
failure. 
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addition to this, it allows for more powerful and 
flexible analysis of subgroups and testing, adjusting 
for confounders. 
OBJECTIVE 
The aim of the proposed study is to perform an IPD 
meta-analysis to determine the relative incidence of 
each organ failure, and the impact that the number, 
timing, duration, sequence, and combination of 
different individual organ failures on mortality in 
patients with acute pancreatitis. 
METHODS AND DESIGN 
Study Design 
The study design will be an individual patient data 
meta-analysis [55, 56, 57, 58]. 
Identification of Studies 
All participants of the recently conducted first 
global survey of pancreatologists, who are active in 
clinical research, will be invited to contribute 
individual patient data to this study [36]. Table 1 
presents the geographic distribution of participants 
in the global survey. Pancreatologists are also 
encouraged to contact the corresponding author of 
this article if they are interested in contributing to 
this project. 
Eligibility Criteria 
To be included, studies will have to meet the 
following criteria: 
• Design: prospective cohort; 
• Population: patients with acute pancreatitis who 
presented with or developed organ failure during 
first week of hospital admission; 
• Exposure: respiratory, renal, and/or cardio-
vascular organ failure; 
• Outcome: in-hospital mortality; 
• Study period: conducted from the year 2000 
onwards. 
Studies/individual data will be excluded if: 
• Participants were enrolled into an interventional 
study; 
• Data do not contain the essential information 
required (see below). 
Collection of Data and Management 
Essential and optional data to be collected are 
shown in Table 2. All the contributors will be asked 
to provide de-identified data by uploading them 
into a standardized data collection form or in any 
convenient format by encrypted, electronic transfer 
where possible or by other means as required, 
depending on site issues. The original data 
collection files sent by the authors will be kept in 
their original version and will be saved on a 
password-protected server at the University of 
Auckland, and behind the firewall to ensure 
security. Only the investigators of PANCREA II study 
will have direct access to individual data prior to 
publication of the final report. 
Transfer of Data 
The data will be transferred to a secure password-
protected web server at University of Auckland or 
by privacy encrypted e-mail. This permits a secure 
and identifiable connection and minimizes the 
possibility of data loss. 
Data Checking 
Study investigators will perform data validation 
using a copy. The data will be checked 
independently with respect to range, internal 
Table 1. Geographic distribution of the PANCREA collaborators. 
Argentina  Malaysia  
Australia  Mexico  
Austria  Netherlands  
Belgium  New Zealand  
Bosnia and Herzegovina  Norway  
Brazil  Peru  
Canada  Philippines  
China  Poland  
Croatia  Romania  
Czech Republic  Russia  
Denmark  Serbia and Montenegro  
Egypt  Slovakia  
Finland  Slovenia  
France  Spain  
Germany  Sweden  
Greece  Switzerland  
Hungary  Taiwan  
India  Thailand  
Iran  Turkey  
Israel  Ukraine  
Italy  United Arab Emirates  
Japan  United Kingdom  
Latvia  United States  
Lithuania  Uruguay  
 
Venezuela  
 
Table 2. Data to be collected. 
Essential data 
Date of admission 
Age 
Sex 
Etiology (Alcohol, Biliary, Other or Unknown) 
Presence/Absence of organ failure in each of three organ systems 
studied in the first week of hospital stay 
Optional data 
Duration of symptoms prior to admission 
Total duration of stay in intensive care unit 
Total hospital stay 
APACHE II score on admission 
CT findings (CT severity index, Balthazar score, etc.) 
Presence/Absence of infected pancreatic necrosis 
Presence/Absence of extra pancreatic infectious complications 
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consistency, missing or extreme values, errors and 
consistency with published reports. Study details, 
such as selection methods and outcome details will 
be crossed-checked against published reports, study 
protocols and data collection spread sheets. 
Apparent inconsistencies, implausibilities, or 
omissions will be clarified with collaborators and, 
where appropriate, rectified. Summary tables and 
listing of the variables used in planned analyses will 
be supplied to collaborators for checking. Any 
discrepancies will be resolved by discussion. 
Collaborators will be asked to verify all recorded 
data before any analysis and the data will not be 
used for any other purposes without permission 
from all the collaborators. 
Core Data Set and Variables 
All verified data will be entered into a master Excel 
spread sheet. A unique identification number will be 
allocated to each patient entered into the core data 
set. This number will easily correspond to patients 
from verified data from individual studies. The 
essential and optional data will be manually entered 
into master spread sheet, and checked. 
Definitions 
Acute pancreatitis will be diagnosed by the 
presence two of the following three features: 
• abdominal pain characteristic of acute 
pancreatitis; 
• serum amylase and/or lipase 3 times the upper 
limit of normal; and 
• characteristic findings of acute pancreatitis on 
tomography (CT) scan. 
Organ failure will be defined as the presence of 
worsened organ function in an acutely ill acute 
pancreatitis patient using one of the following 
criteria: 
• “breaching of thresholds” as described by 
Bradley et al. [22] with shock defined as a systolic 
blood pressure less than 90 mmHg, pulmonary 
insufficiency defined as PaO2 of 60 mmHg or less, 
renal failure defined as a creatinine level greater 
than 177 µmol/L (2 mg/dL) after rehydration; 
• a SOFA score of 2 or more for each individual 
system [29]; 
• a Marshall score of 2 or more for each individual 
system [59]. 
The organ systems that will be reported on include 
respiratory, cardiovascular and renal systems. The 
definitions used in relation to the timing, duration, 
sequence and combination of organ failures are 
given in Figure 2. 
Total hospital stay will be defined as the number of 
consecutive days the patient was in hospital. 
Duration of symptoms will be defined as the 
number of consecutive full days (24 hours) the 
patient had symptoms before the day of admission, 
excluding the day of admission. 
Planned Statistical Analysis 
Due to the complexity of the statistical analyses, the 
following section represents the planned principal 
analyses; some modifications and secondary 
analyses are likely to emerge during the project. 
However, a detailed statistical analysis plan will be 
produced before the analysis. Any analysis 
conducted will be based on the checked and 
updated IPD from all available studies. 
Primary Analysis 
A “one-stage” approach will be used because of its 
increased power and ability to test for nonlinear 
relationships for continuous variables and ability to 
control for aggregation bias [53, 58, 60, 61, 62]. The 
model used will be based on a logistic regression 
model [52] adjusted for confounding variables 
including age, sex, etiology, etc. The dependent 
variable will be mortality and independent 
variables will initially include the characteristics of 
organ failure (timing, duration, sequence, and 
combination of organ failures). The R 2.15.2 
framework (R Foundation for Statistical Computing, 
Vienna, Austria) will be used for statistical analysis 
[63]. 
Summary statistics with corresponding 95% 
confidence intervals (CIs) will be calculated. This 
will include the pooled incidence of each system 
failure. Patients will be grouped according to total 
number of organ failures at any point and pooled 
incidence for one, two, three organ failures will be 
calculated with corresponding mortality rates. 
Patients will also be grouped according to timing of 
first (any) organ failure and mortality rates and 
relative risks will be calculated according to organ 
failure occurring at any particular day during the 
first week. Further analysis will be performed based 
Figure 2. Outcome definitions for the studied characteristics of 
organ failure. 
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on duration of organ failure. Relative risks of death 
will be calculated for patients with organ failure for 
one day only compared to organ failure for more 
than one day. The same analysis will be done for 
organ failure for two days compared to organ 
failure for more than two days and so on (three and 
four days). 
Patients with two or three organ failures with 
different sequences of organ failures will be 
grouped together and the pooled incidence of each 
sequence of organ failure will be calculated. 
Lastly, patients will be grouped according to 
different combinations of two organ failure and 
relative risks of death will be calculated. These 
combinations will include cardiovascular and 
respiratory, cardiovascular and renal, respiratory 
and renal systems. 
Subgroup Analysis 
The cohorts will be grouped according to the 
provision of optional data. These will be listed 
firstly in a summary table with the following 
headings: study title, number of patients, data 
available (yes/no) for covariates: durations of 
symptoms, APACHE II score on admission, extent of 
necrosis on CT, CT severity index, infectious 
pancreatic complications during hospitalization, 
other infectious complications during hospital-
ization, as well as data available for secondary 
outcomes: duration of ICU stay and total hospital 
stay. If sufficient patient numbers are available, 
analysis will then be conducted for each covariate in 
separate subgroups. The same model used in the 
primary analysis will also be applied for secondary 
outcomes if sufficient data are available. 
Secondary Analysis 
Further analyses may include possible confounding 
factors for the entire patient population identified 
from our subgroups analysis. Subsequent analysis 
from the primary analysis will adjust for any 
additional confounders using multivariate 
regression to give estimates that are more relevant 
to individual patients. 
Data Presentation 
Baseline characteristics of patients will be 
presented for individual cohorts as well as overall 
summary statistics. Continuous variables will be 
presented as mean and standard deviation (or 
median and range if not normally distributed). 
Binary and categorical outcomes will be presented 
as frequency and percentages. We will also report 
mortality rates both before and after adjustments 
for confounders. 
For all primary and secondary analyses, adjusted 
risk ratios and corresponding 95% CIs will be 
presented, along with the corresponding P values. P 
values less than 0.05 will be regarded as statistically 
significant. The final meta-analysis will be reported 
based on relevant guidelines [64, 65]. 
Publication Policy 
The main results of this project will be published 
and presented under the auspices of the 
Pancreatitis Across Nations Clinical Research and 
Education Alliance (PANCREA). Up to two 
researchers from each contributing centre and the 
PANCREA Steering Committee will be invited to 
author the manuscript. Results from further papers 
using the same data set will not be published 
without approval from all collaborators and will 
acknowledge the PANCREA collaboration as the 
source of the data. The PANCREA collaboration will 
disseminate the findings of its research widely at 
academic conferences and in journal publications. 
DISCUSSION 
Organ failure is one of main causes of death in 
patients with acute pancreatitis but, to date, there 
has been a lack of quality data on its natural course 
and characteristics that influence patients’ 
outcomes. Part of the drive to improve patients’ 
outcomes will require a better understanding of the 
different characteristics of organ failure. The best 
way to advance this is to aggregate existing 
prospective data from non-interventional studies 
under the auspice of an international collaboration. 
This approach allows for more powerful and flexible 
analysis of subgroups and testing, adjusting for 
confounders and minimizes publication and 
reporting bias [66] and has been described as the 
“gold standard” of evidence synthesis [55, 56, 57]. 
The PANCREA collaboration has already been 
established and its first study was to develop a new 
classification for the severity of acute pancreatitis 
[1]. This involved several stages. The first stage was 
an evidence review to recognize a need for a new 
classification for the severity of acute pancreatitis 
and to highlight the limitations of previous 
classifications. The second stage was conducting a 
world-wide survey of pancreatologists. The third 
stage was to further discuss the proposed 
classification and seek accord on definitions at an 
international symposium during the 2011 Meeting 
of the International Association of Pancreatology 
(Kochi, India). The final document was published as 
a feature article in the world’s premier surgical 
journal and was accompanied by a supportive 
editorial by the author of the Atlanta classification 
[67]. The new classification has also become 
available in several languages other than English 
[68, 69, 70, 71]. 
The study described in this protocol will be the 
second multicentre study of the PANCREA 
collaborative (PANCREA II study). It will attempt to 
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answer important questions regarding the effect of 
timing, duration, sequence and combination of 
individual organ system failures on mortality. 
Information derived from this study will be used to 
optimize routine clinical management and improve 
clinical care strategies. These will then help in the 
direction of health resources and improve cost 
effectiveness. It can also help validate outcome 
definitions, allow comparability of results and form 
a more accurate basis for patient allocation in 
further clinical studies. 
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